Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Somnomed stock

SOM.AX
AU000000SOM1
A0B7QA

Price

0.60
Today +/-
+0
Today %
+0 %

Somnomed stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Somnomed stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Somnomed stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Somnomed stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Somnomed's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Somnomed Stock Price History

DateSomnomed Price
2/28/20250.60 undefined
2/27/20250.60 undefined
2/26/20250.60 undefined
2/25/20250.57 undefined
2/24/20250.60 undefined
2/21/20250.61 undefined
2/20/20250.59 undefined
2/19/20250.59 undefined
2/18/20250.61 undefined
2/17/20250.62 undefined
2/14/20250.62 undefined
2/13/20250.63 undefined
2/12/20250.64 undefined
2/11/20250.64 undefined
2/10/20250.64 undefined
2/7/20250.65 undefined
2/6/20250.65 undefined
2/5/20250.65 undefined
2/4/20250.63 undefined
2/3/20250.63 undefined

Somnomed Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Somnomed, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Somnomed from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Somnomed’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Somnomed. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Somnomed’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Somnomed’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Somnomed’s growth potential.

Somnomed Revenue, EBIT and net profit per share

DateSomnomed RevenueSomnomed EBITSomnomed Net Income
2027e127.87 M undefined4.63 M undefined3.16 M undefined
2026e116.71 M undefined3.22 M undefined2.07 M undefined
2025e107.67 M undefined2.03 M undefined873,084.4 undefined
202491.68 M undefined-8.3 M undefined-12.24 M undefined
202383.62 M undefined-4.07 M undefined-8 M undefined
202272.58 M undefined-4.13 M undefined-4.44 M undefined
202162.71 M undefined-851,000 undefined-1.19 M undefined
202057.31 M undefined-928,000 undefined-1.12 M undefined
201958.92 M undefined947,000 undefined-16.44 M undefined
201863.81 M undefined-8.67 M undefined-8.62 M undefined
201749.45 M undefined-3.61 M undefined-3.34 M undefined
201644.14 M undefined174,000 undefined165,000 undefined
201534.59 M undefined188,000 undefined597,000 undefined
201430.3 M undefined340,000 undefined406,000 undefined
201318.58 M undefined297,000 undefined589,000 undefined
201215.37 M undefined583,000 undefined525,000 undefined
201112.43 M undefined615,000 undefined740,000 undefined
201010.8 M undefined107,000 undefined786,000 undefined
20097.97 M undefined-1.74 M undefined-1.82 M undefined
20083.95 M undefined-2.58 M undefined-2.73 M undefined
20072.27 M undefined-3.41 M undefined-3.28 M undefined
20061.79 M undefined-4.41 M undefined-4.19 M undefined
2005377,000 undefined-4.07 M undefined-3.69 M undefined

Somnomed Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
0001237101215183034444963585762728391107116127
----100.0050.00133.3342.8620.0025.0020.0066.6713.3329.4111.3628.57-7.94-1.728.7716.1315.289.6417.588.419.48
---5,500.0050.0066.6757.1460.0066.6766.6766.6753.3355.8856.8257.1460.3258.6257.8959.6861.1161.4560.4451.4047.4143.31
00001246810121619252838343337445155000
00-3-4-3-2-10000000-3-8-16-1-1-4-7-12023
---33.33-25.00-33.33-50.00--------166.67100.00-93.75-300.0075.0071.43--50.00
0.653.9617.4618.5428.4251.9560.9361.8864.4765.6967.3170.2179.2682.1884.587.5391.4785.31105.97106.15106.15120.73000
-------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Somnomed Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Somnomed is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                           
0.120.056.642.313.215.434.014.293.953.544.222.958.3117.6314.2113.387.730.1721.1115.6411.9616.18
00.010.130.320.30.571.181.31.883.223.924.355.36.066.6210.47.124.096.667.387.2212.36
00.02000.080.180.060.230.320.50.471.151.881.793.583.183.442.041.571.831.810.32
0000.020.010.030.080.20.180.50.850.971.291.691.9521.92.242.333.094.16.29
0000000.180.0500.0200000001.692.462.382.410
0.120.086.772.643.596.215.526.076.337.789.469.4116.7827.1726.3628.9720.1640.2334.1330.3127.535.14
00.030.660.990.720.460.240.641.141.071.161.252.113.574.496.613.2510.2410.349.1212.7311.15
0000000298516022300000000000
00000000000000265479141204792644057
00.520.490.440.390.340.280.230.330.490.450.40.410.380.460.491.371.462.329.4112.4820.32
0000000001.324.865.695.486.246.176.386.416.476.266.046.490
00000000.860.851.182.162.42.993.063.472.783.433.093.042.953.253.14
00.551.151.431.110.790.521.762.44.228.849.7410.9713.2614.8616.7314.5921.4622.0427.783534.67
0.120.637.924.074.77.016.047.838.731218.319.1427.7540.4341.2145.734.7561.6956.1758.0962.4969.81
                                           
44.2814.9114.9118.5723.2723.2723.7124.0425.3926.0726.4733.7144.5546.9457.7457.6873.9474.2674.2774.27110.23
0000000000000000000000
-3.89-4.44-7.71-11.69-14.66-17.21-18.89-18.02-17.15-16.54-15.43-14.71-13.91-13.26-14.72-21.62-42.44-43.14-44.3-47.55-54.51-65.21
0000.010-0.05-0.05-0.04-0.67-0.430.760.581.541.84002.583.032.21.062.640
0000000000000000000000
0.12-0.167.23.233.916.014.335.656.228.4111.412.3421.3433.1332.2136.1217.8233.8332.1627.7922.445.02
00.430.250.450.610.841.261.71.662.53.083.053.716.077.558.087.838.2810.3312.591213.29
00000000000.580.590.680.671.511.971.791.952.222.432.190
00.360.050.140.080.160.450.490.850.881.131.11.080.840.831.083.191.271.692.11.614.05
00000000000000003.014.9504.880.310.31
000.160.160.090000000000.070.40.232.331.961.782.262.3
00.780.460.740.7911.712.182.513.384.784.745.477.589.9511.5416.0518.7816.223.7718.3619.94
000.260.0900000000000.051.040.368.256.955.3520.944.12
0000000000000000000000
000000000.010.011.951.840.770.160.260.350.530.830.861.180.790.72
000.260.0900000.010.011.951.840.770.160.311.390.899.087.816.5321.734.84
00.780.720.840.7911.712.182.513.396.736.576.247.7410.2612.9316.9327.8624.0130.340.0924.78
0.120.627.924.074.77.016.047.838.7311.818.1318.9127.5840.8742.4749.0534.7561.6956.1758.0962.4969.81
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Somnomed provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Somnomed's financial health and stability.

Assets

Somnomed's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Somnomed must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Somnomed after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Somnomed's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (k)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
000000000000000000-1-4-8
000000000000000000333
000000000000000000000
000000000000000000000
000000000000000000001,000
00000000000000000000-1
00000000000000-100000-1
00-3-3-2-2-10000002-2-9-6521-3
000000000000-1-2-2-2-1-2-4-8-6
00-1000000000-1-3-2-2-1-1-4-8-6
0000000000000-10000000
000000000000000000000
000000000000000022-726
0010034000000710211016000
0011034000000710210218-626
---------------------
000000000000000000000
002-8-10-30001-1511-5-10-1129-5-2-3
-0.03-0.3-4.1-4.17-2.36-2.24-1.42-0.07-0.46-0.190.27-1.19-1.560.1-5.31-11.64-8.213-1.43-6.93-10.29
000000000000000000000

Somnomed stock margins

The Somnomed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Somnomed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Somnomed.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Somnomed's sales revenue. A higher gross margin percentage indicates that the Somnomed retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Somnomed's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Somnomed's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Somnomed's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Somnomed. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Somnomed's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Somnomed Margin History

Somnomed Gross marginSomnomed Profit marginSomnomed EBIT marginSomnomed Profit margin
2027e60.17 %3.62 %2.48 %
2026e60.17 %2.75 %1.78 %
2025e60.17 %1.89 %0.81 %
202460.17 %-9.05 %-13.35 %
202362.1 %-4.86 %-9.57 %
202261.01 %-5.69 %-6.11 %
202160.19 %-1.36 %-1.9 %
202057.78 %-1.62 %-1.95 %
201958.73 %1.61 %-27.9 %
201860.16 %-13.59 %-13.51 %
201758.51 %-7.3 %-6.76 %
201657.54 %0.39 %0.37 %
201556.79 %0.54 %1.73 %
201455.56 %1.12 %1.34 %
201366.52 %1.6 %3.17 %
201268.19 %3.79 %3.42 %
201166.54 %4.95 %5.95 %
201057.15 %0.99 %7.28 %
200953.82 %-21.86 %-22.83 %
200856.96 %-65.26 %-69.08 %
200744.08 %-149.93 %-144.08 %
200644.85 %-247.03 %-234.49 %
20057.43 %-1,078.25 %-979.31 %

Somnomed Stock Sales Revenue, EBIT, Earnings per Share

The Somnomed earnings per share therefore indicates how much revenue Somnomed has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Somnomed earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Somnomed's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Somnomed’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Somnomed's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Somnomed Revenue, EBIT and net profit per share

DateSomnomed Sales per ShareSomnomed EBIT per shareSomnomed Earnings per Share
2027e0.59 undefined0 undefined0.01 undefined
2026e0.54 undefined0 undefined0.01 undefined
2025e0.5 undefined0 undefined0 undefined
20240.76 undefined-0.07 undefined-0.1 undefined
20230.79 undefined-0.04 undefined-0.08 undefined
20220.68 undefined-0.04 undefined-0.04 undefined
20210.59 undefined-0.01 undefined-0.01 undefined
20200.67 undefined-0.01 undefined-0.01 undefined
20190.64 undefined0.01 undefined-0.18 undefined
20180.73 undefined-0.1 undefined-0.1 undefined
20170.59 undefined-0.04 undefined-0.04 undefined
20160.54 undefined0 undefined0 undefined
20150.44 undefined0 undefined0.01 undefined
20140.43 undefined0 undefined0.01 undefined
20130.28 undefined0 undefined0.01 undefined
20120.23 undefined0.01 undefined0.01 undefined
20110.19 undefined0.01 undefined0.01 undefined
20100.17 undefined0 undefined0.01 undefined
20090.13 undefined-0.03 undefined-0.03 undefined
20080.08 undefined-0.05 undefined-0.05 undefined
20070.08 undefined-0.12 undefined-0.12 undefined
20060.1 undefined-0.24 undefined-0.23 undefined
20050.02 undefined-0.23 undefined-0.21 undefined

Somnomed business model

SomnoMed Ltd is a leading medical technology company based in Sydney, Australia. It was founded in 2004 and specializes in the development and distribution of medical devices for the treatment of sleep apnea and bruxism. Somnomed is one of the most popular companies on Eulerpool.com.

Somnomed SWOT Analysis

Strengths

Somnomed Ltd has several strengths that give it a competitive advantage in the market. These strengths include:

  • Strong brand reputation and recognition in the industry.
  • High-quality products and advanced technology.
  • Wide distribution network and global presence.
  • Strong relationships with key stakeholders, including dentists and sleep physicians.
  • Established customer base and loyal clientele.

Weaknesses

Despite its strengths, Somnomed Ltd also faces certain weaknesses that could hinder its growth and performance. These weaknesses include:

  • Relatively higher product pricing compared to competitors.
  • Dependency on a limited number of suppliers for essential raw materials.
  • Limited product portfolio offering, focusing primarily on oral devices.
  • Possibility of product recalls impacting company reputation.
  • Higher costs associated with research and development.

Opportunities

Somnomed Ltd can capitalize on various opportunities in the market to further expand its business. These opportunities include:

  • Increasing prevalence of sleep disorders globally, providing a growing market demand.
  • Expansion into emerging markets with a rising awareness of sleep disorders.
  • Development of innovative products to cater to specific patient needs.
  • Collaboration with healthcare providers to promote the importance of sleep disorder treatment.
  • Integration of digital technologies to enhance customer experience and provide remote monitoring.

Threats

However, Somnomed Ltd also faces threats that may pose challenges to its growth and sustainability. These threats include:

  • Intense competition from existing and new market entrants.
  • Stringent regulatory requirements for medical devices and treatments.
  • Economic downturn or fluctuations impacting consumer purchasing power.
  • Emergence of alternative treatment options for sleep disorders.
  • Negative publicity or legal issues related to product safety or efficacy.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Somnomed Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Somnomed historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Somnomed shares outstanding

The number of shares was Somnomed in 2024 — This indicates how many shares 120.727 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Somnomed earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Somnomed's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Somnomed’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Somnomed's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Somnomed stock splits

In Somnomed's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Somnomed.

Somnomed latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0 -0.03  (-833.33 %)2024 Q4
12/31/2023-0.02 -0.05  (-155.21 %)2024 Q2
6/30/2023-0.02 -0.03  (-97.91 %)2023 Q4
1

Somnomed shareholders

%
Name
Stocks
Change
Date
31.33408 % TDM Growth Partners67,716,079010/8/2024
15.84557 % Australian Ethical Investment Ltd.34,243,8609,713,0925/8/2024
8.23673 % FIL Investment Management (Hong Kong) Limited17,800,38905/8/2024
3.05797 % Dottie Investments Pty. Ltd.6,608,56940,3199/12/2023
2.13680 % Equity T S Pty. Ltd.4,617,834-36,4349/12/2023
2.04657 % Fidelity Management & Research Company LLC4,422,833-1,548,81112/22/2023
1.24034 % Howarth PAF Pty. Ltd.2,680,49309/12/2023
0.95010 % Belgove Pty. Ltd.2,053,26509/12/2023
0.80470 % Ginga Pty. Ltd.1,739,04510,0009/12/2023
0.73622 % Equity Plan Services Pty. Ltd.1,591,0501,591,0502/22/2024
1
2
3

Somnomed Executives and Management Board

Mr. Neil Robert Verdal-austin

Somnomed Chief Executive Officer, Managing Director
Compensation 1.04 M

Mr. Matthew Conlon

Somnomed Executive Vice President – Marketing and Sales North America
Compensation 569,191

Mr. Mark Harding

Somnomed Vice President - Global Marketing
Compensation 490,938

Mr. Marco Van Kleef

Somnomed Vice President – Marketing & Sales Europe
Compensation 320,031

Mr. Guy Russo

(64)
Somnomed Non-Executive Chairman of the Board
Compensation 184,227
1
2
3

Somnomed Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Australian Ethical Investment Stock
Australian Ethical Investment
SupplierCustomer0,740,350,530,870,74
HSBC Holdings Stock
HSBC Holdings
SupplierCustomer-0,450,600,38-0,57-0,66
1

Most common questions regarding Somnomed

What values and corporate philosophy does Somnomed represent?

Somnomed Ltd represents values of excellence, innovation, and patient-centered care. With a strong corporate philosophy, the company is committed to improving the sleep health and quality of life for individuals suffering from sleep-related breathing disorders. Somnomed Ltd prioritizes the development and delivery of high-quality, clinically proven oral devices that provide effective treatment options for patients. By leveraging cutting-edge technology and a patient-focused approach, Somnomed Ltd aims to enhance sleep medicine and promote healthier sleep patterns worldwide.

In which countries and regions is Somnomed primarily present?

Somnomed Ltd is primarily present in various countries and regions across the globe. The company has a strong presence in North America, including the United States and Canada, where it offers its innovative sleep apnea solutions. Additionally, Somnomed Ltd has established a significant foothold in Europe, catering to patients in countries such as Germany, France, Italy, and the United Kingdom. It also operates in the Asia-Pacific region, with key markets including Australia, New Zealand, and Japan. With its international reach, Somnomed Ltd continuously expands its presence to address the needs of individuals suffering from sleep-disordered breathing worldwide.

What significant milestones has the company Somnomed achieved?

Since its establishment, Somnomed Ltd has reached several significant milestones. The company has successfully developed and patented innovative medical devices, such as SomnoDent, which is widely recognized as a leading oral appliance therapy for obstructive sleep apnea. Somnomed Ltd has also expanded its global footprint, establishing a strong presence across major markets like the United States, Europe, and Asia-Pacific. Over the years, the company has fostered strong relationships with dental and medical professionals while continuously investing in research and development. With a commitment to improving the lives of patients suffering from sleep-related breathing disorders, Somnomed Ltd continues to drive innovation and deliver excellent treatment solutions.

What is the history and background of the company Somnomed?

Somnomed Ltd is a leading company in the dental sleep medicine industry. Established in 2004, it has become a global leader in providing innovative solutions for the treatment of sleep-related breathing disorders such as sleep apnea. With headquarters in Australia, Somnomed has expanded its presence worldwide, offering state-of-the-art oral appliances that improve patients' quality of life. The company has a strong commitment to research and development, continuously striving to deliver advanced technologies and improve treatment outcomes. Through its dedication to excellence, Somnomed has garnered a reputation for its high-quality products and undisputed expertise, making it a trusted choice for both patients and healthcare professionals.

Who are the main competitors of Somnomed in the market?

The main competitors of Somnomed Ltd in the market include companies such as ResMed Inc., i3DiCAM, and Panthera Dental. These companies compete with Somnomed Ltd in the field of sleep apnea and dental solutions. ResMed Inc. is a leading global provider of medical equipment, focusing on sleep apnea and other respiratory disorders. i3DiCAM specializes in 3D imaging and CAD/CAM solutions for dental applications. Panthera Dental offers innovative dental sleep solutions and services. While Somnomed Ltd holds a strong market position with its range of oral devices and sleep apnea treatments, it faces competition from these established players in the industry.

In which industries is Somnomed primarily active?

Somnomed Ltd is primarily active in the medical device industry, specifically focusing on the treatment of sleep-related breathing disorders. With its innovative oral appliance therapy, the company provides effective solutions for patients suffering from conditions such as sleep apnea. As a leader in dental sleep medicine, Somnomed Ltd partners with healthcare professionals worldwide to improve the quality of life for individuals affected by sleep disorders.

What is the business model of Somnomed?

The business model of Somnomed Ltd revolves around the manufacturing and selling of medical devices to treat patients with sleep-related breathing disorders such as obstructive sleep apnea (OSA). Somnomed specializes in creating oral devices known as mandibular advancement splints (MAS) that are worn during sleep to help keep the airway open and improve breathing. These custom-designed devices are crafted using dental impressions and are prescribed by healthcare professionals. Somnomed focuses on delivering innovative and high-quality solutions to help patients improve their quality of sleep and overall well-being.

What is the P/E ratio of Somnomed 2025?

The Somnomed P/E ratio is 82.97.

What is the P/S ratio of Somnomed 2025?

The Somnomed P/S ratio is 0.67.

What is the Quality Investing of Somnomed?

The Quality Investing for Somnomed is 5/10.

What is the revenue of Somnomed 2025?

The expected Somnomed revenue is 107.67 M AUD.

How high is the profit of Somnomed 2025?

The expected Somnomed profit is 873,084.4 AUD.

What is the business model of Somnomed

SomnoMed Ltd is a leading player in the field of sleep medicine and specializes in the manufacturing and distribution of sleep medical devices. The company was founded in 2004 and is headquartered in Australia. However, it has a significant presence worldwide in Europe, North America, and the Asia-Pacific region. The business model of SomnoMed Ltd is based on the development, manufacturing, and distribution of sleep medical devices for the treatment of sleep apnea and snoring. The company offers a wide range of products, including SomnoDent® devices, a recognized non-CPAP solution for the treatment of obstructive sleep apnea. These devices work by gently increasing the lower jaw and tongue to open the airway passage and alleviate snoring and symptoms of obstructive sleep apnea. The company collaborates with a network of medical device dealers and sleep medicine professionals to sell and distribute its products. SomnoMed Ltd also has excellent relationships with insurers and healthcare providers to ensure that the treatment of sleep apnea is covered by their devices. SomnoMed Ltd offers value-added services such as training and support. In Europe, the company maintains its own production facility in Germany to meet the demand of local markets for specialized devices. SomnoMed is also committed to expanding and improving its product range through continuous research and development activities. SomnoMed Ltd also has an online presence and offers various online tools to assist customers in finding a sleep medicine professional near them or reviewing their insurance coverage. The company has also developed online training to educate sleep medicine professionals and customer service representatives involved in the care of patients using the SomnoMed product range. The different divisions of SomnoMed Ltd include the sleep medicine segment and the healthcare segment. The company's sleep medical devices are primarily intended for the treatment of sleep apnea and snoring. The aim of these devices is to improve the patient's breathing during sleep and thereby increase their quality of life. SomnoMed Ltd is also involved in the field of dental sleep medicine, and its devices are prescribed by sleep medicine professionals and dentists. The healthcare segment of SomnoMed Ltd focuses on healthcare services and also includes the manufacturing and distribution of medical products. The company offers training and support for its products to assist healthcare professionals in their application and patient care. In the coming years, the company is expected to continue its expansion of geographic reach, product development, and collaboration with physicians and sleep medicine professionals. The focus is on expanding market share in sleep medicine through the development of innovative products and the expansion of the distribution network.

What is the Somnomed dividend?

Somnomed pays a dividend of 0 AUD distributed over payouts per year.

How often does Somnomed pay dividends?

The dividend cannot currently be calculated for Somnomed or the company does not pay out a dividend.

What is the Somnomed ISIN?

The ISIN of Somnomed is AU000000SOM1.

What is the Somnomed WKN?

The WKN of Somnomed is A0B7QA.

What is the Somnomed ticker?

The ticker of Somnomed is SOM.AX.

How much dividend does Somnomed pay?

Over the past 12 months, Somnomed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Somnomed is expected to pay a dividend of 0 AUD.

What is the dividend yield of Somnomed?

The current dividend yield of Somnomed is .

When does Somnomed pay dividends?

Somnomed pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Somnomed?

Somnomed paid dividends every year for the past 0 years.

What is the dividend of Somnomed?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Somnomed located?

Somnomed is assigned to the 'Health' sector.

Wann musste ich die Aktien von Somnomed kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Somnomed from 3/3/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 3/3/2025.

When did Somnomed pay the last dividend?

The last dividend was paid out on 3/3/2025.

What was the dividend of Somnomed in the year 2024?

In the year 2024, Somnomed distributed 0 AUD as dividends.

In which currency does Somnomed pay out the dividend?

The dividends of Somnomed are distributed in AUD.

All fundamentals about Somnomed

Our stock analysis for Somnomed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Somnomed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.